NASDAQ · RGEN
Repligen Corporation
$188.64+$3.95 (+2.14%)
Repligen Corporation’s quoted price sits in the upper half of its reported 52-week range, 5.14% below the high.
Loading market information…
NASDAQ · MRVI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Maravai LifeSciences Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.19% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Maravai LifeSciences Holdings, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Maravai LifeSciences Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $47.40M-5.36% vs estimate |
| Q1 2025 | May 12, 2025 | -$0.08-14.29% vs estimate | $46.85M+6.46% vs estimate |
|---|
| Q4 2024 | Mar 18, 2025 | -$0.06-100.0% vs estimate | $56.41M-2.39% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.02-150.0% vs estimate | $65.20M+15.1% vs estimate |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $7.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$188.64+$3.95 (+2.14%)
Repligen Corporation’s quoted price sits in the upper half of its reported 52-week range, 5.14% below the high.
$72.71+$0.02 (+0.03%)
Bio-Techne Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$384.40-$0.72 (-0.19%)
Bio-Rad Laboratories, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.99% below the high.
$12.26+$0.14 (+1.16%)
Neogen Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.03% below the high.
$38.61$0.00 (0.0%)
BioLife Solutions, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.89% below the high.
$41.27+$0.64 (+1.58%)
Azenta, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.08% below the high.
$2.90+$0.07 (+2.47%)
Pacific Biosciences of California, Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.7% below the high.
$0.62+$0.00 (+0.49%)
Standard BioTools Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.95% below the high.
